Relief confirmed release of preliminary findings from phase 2b/3 trial of intravenous RLF-100ﾙ (aviptadil)
On Feb. 10, 2021, RELIEF THERAPEUTICS announced the release of preliminary results from the phase 2b/3 trial of…
-
-
USDA confirmed COVID-19 in a cougar and tiger at a wild animal exhibitor in Texas
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
-
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
-
BioNTech updated vaccine production manufacturing site in Marburg, Germany
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
-
XPhyto added mescaline production to psychedelic medicine programs
On Feb. 10, 2021, XPhyto announced it had added mescaline production to its psychedelic medicine programs. Further to…
-
Moderna announced COVID-19 vaccine supply agreements with governments of Taiwan and Colombia
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
-
FDA authorized Eli Lilly’s monoclonal antibodies for treatment of COVID-19
On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab…
-
Oxford Immunotec entered MOU with Green Cross to market T-SPOT Discovery SARS-CoV-2 Kit in South Korea
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
-
Clinical trial in hospitalized COVID-19 patients evaluate long-acting antibody therapy
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
-
NanoViricides’s antiviral drug candidate for treatment of COVID-19 infections well tolerated in animal safety studies
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
-
Repligen and Navigo Proteins announced the launch of affinity resin for the purification of COVID-19 vaccines
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they have completed the development and initiated the commercial…
-
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
-
Tonix Pharmaceuticals to develop COVID-19 skin test to measure SARS-CoV-2 exposure and T cell immunity
On Feb. 8, 2021, Tonix Pharmaceuticals announced it had received the written response from the U.S. Food and…
-
US COVID-19 infections nearly three times greater than reported, UTSW model estimated
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
-
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
-
Resurgence of Ebola reported in North Kivu in the Democratic Republic of the Congo
On Feb. 7, 2021, The Ministry of Health of the Democratic Republic of the Congo (DRC) announced that…
-
FDA approved new treatment for adults with relapsed or refractory large-B-Cell lymphoma
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
-
CureVac and UK Government announced collaboration on development of vaccines against SARS-CoV-2 variants
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
-
The Wellcome Sanger Institute announced sequencing 136,383 Coronavirus genomes in the UK
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
-
Oxford University vaccine effective against major B117 ‘Kent’ coronavirus strain circulating in the UK
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxford’s…
-
Merck Statement on Ivermectin use During the COVID-19 Pandemic
On Feb. 4, 2021, Merck affirmed its position regarding use of ivermectin during the COVID-19 pandemic, and do…
-
T2 Biosystems T2SARS-CoV-2 panel proved capable of detecting the Brazil P1 variant of SARS-CoV-2 virus
On Feb. 4, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel – a molecular diagnostic test that detects…
-
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
-
COVAX expected to start sending millions of COVID-19 vaccines to Africa in February
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
-
The US Department of Defense announced use of masks and other public health measures
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
-
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
-
Johnson & Johnson announced submission of application to FDA for EUA of its single-shot COVID-19 vaccine candidate
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
-
Oxford Immunotec updated T-SPOT Discovery SARS-CoV-2 kit to detect T Cells reactive to endemic Coronaviruses
On Feb. 4, 2021, Oxford Immunotec announced an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit….
-
NeuroRx initiated phase 2/3 study of inhaled ZYESAMI for severe COVID-19 with UCI Health
On Feb. 3, 2021, RELIEF THERAPEUTICS affirmed that its collaboration partner NeuroRx had initiated a phase 2/3 clinical…
-
Bristol Myers and Rockefeller University announced license agreement for SARS-CoV-2 meutralizing mAb combination
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
